PTE - PolarityTE, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0700
+0.1600 (+5.50%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.9100
Open3.0000
Bid0.0000 x 2200
Ask0.0000 x 1100
Day's Range2.9500 - 3.4000
52 Week Range2.1000 - 18.1700
Volume480,550
Avg. Volume328,747
Market Cap87.324M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.7020
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-01-12
1y Target Est13.17
  • Business Wire

    PolarityTE Reports Third Calendar Quarter 2019 Results

    PolarityTE, Inc. , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2019.

  • Business Wire

    PolarityTE Adopts Short-Term Shareholder Rights Plan

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that its Board of Directors approved a short-term shareholder rights agreement (“the Rights Agreement”) following an evaluation by the Shareholder Rights Committee established by the Board in August 2019. The Rights Agreement is intended to ensure that all PolarityTE shareholders receive fair treatment in any potential transaction, while allowing the Board and shareholders adequate time to make informed strategic decisions that the Board and the Company’s executive management team are currently evaluating. The Rights Agreement is not intended to deter offers that are fair and otherwise in the best interests of PolarityTE’s shareholders.

  • Business Wire

    PolarityTE to Report Calendar Third Quarter Financial Results on November 12, 2019

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report calendar third quarter 2019 financial results by press release on Tuesday, November 12, 2019 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Tuesday, November 12, 2019 at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-866-548-4713 (U.S. and Canada) or +44 (0)330 336 9105 (International) with confirmation code 6761138 and referencing “PolarityTE Third Quarter 2019 Earnings Call.” A webcast of the conference call can be accessed by using the link below.

  • PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a measure of share...

  • Business Wire

    PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NGHC), Natural Health Trends Corp. (NHTC), Omnicell, Inc. (OMCL), and PolarityTE, Inc. (PTE) on behalf of long-term stockholders.  More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of National General Holdings Corp. following a class action complaint that was filed against National General on July 25, 2019.

  • Business Wire

    SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that two abstracts demonstrating the impact of the Company’s SkinTE™ product in treating diabetes-related wounds were accepted for poster presentations at the 2019 Diabetic Foot Global Conference (DFCon), an international, interdisciplinary diabetic foot conference hosted by the Keck School of Medicine of University of Southern California in collaboration with Baylor College of Medicine and University of California San Francisco from October 17-19, 2019 in Los Angeles. Today’s announcement further signifies the Company’s momentum with its clinical research program, bringing the total SkinTE data presentations at medical conference in 2019 to 36, of which 14 were podium presentations.

  • SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
    PR Newswire

    SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting

    Podium Presentation to Highlight a Variety of SkinTE Clinical Results in Trauma, Wound, and Burn from a 15 Patient Case Series SALT LAKE CITY , Sept. 9, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: ...

  • PolarityTE Appoints Peter Cohen as Chairman of the Board
    PR Newswire

    PolarityTE Appoints Peter Cohen as Chairman of the Board

    SALT LAKE CITY, Sept. 4, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board. "It gives me great satisfaction to lead the Board during this important time at PolarityTE.  I am proud to be part of a company with such an innovative technology, which not only addresses an unmet medical need, but has the potential to become a mainstay treatment in the field of skin and tissue regeneration," said Mr. Cohen.  "There have been growing pains and unexpected challenges in the development of PolarityTE, which can occur with innovative companies, especially those that have the potential to disrupt the biotechnology industry.  I am pleased with the strides we have made to address these growing pains and challenges, and believe we have the right, disciplined approach to best position the business for growth.

  • PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference

    SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 in New York, NY. PolarityTE also announced that it will attend and meet with investors during the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York, NY. PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%
    Simply Wall St.

    Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%

    PolarityTE, Inc. (NASDAQ:PTE) shareholders should be happy to see the share price up 11% in the last week. But that...

  • PolarityTE Granted Canadian Patent
    PR Newswire

    PolarityTE Granted Canadian Patent

    SALT LAKE CITY , Aug. 20, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that ...

  • PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
    PR Newswire

    PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds

    SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.

  • PolarityTE Reports Second Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports Second Calendar Quarter 2019 Results

    SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
    PR Newswire

    PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019

    SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 8, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-394-8218 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 1393700 and referencing "PolarityTE Second Quarter 2019 Earnings Call".  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Enters Oversold Territory
    Zacks

    PolarityTE Enters Oversold Territory

    PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?
    Insider Monkey

    Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?
    Simply Wall St.

    What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?

    The big shareholder groups in PolarityTE, Inc. (NASDAQ:PTE) have power over the company. Institutions will often hold...

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • Benzinga

    PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

    PolarityTE presented final results from a pilot study on the use of its SkinTE product for hard-to-treat diabetic foot ulcers, or DFUs, as a poster, which showed that 10 of the 11 patients evaluated in the study had healed DFUs within eight weeks of SkinTE application, with a mean time to heal of 29.7 days. SkinTE is an autologous, homologous human cellular and tissue-based product capable of regenerating full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. PolaityTE said the abstract will be published in the online supplement to the journal Diabetes later this year.

  • PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
    PR Newswire

    PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE

    SALT LAKE CITY, June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs). The data was presented at the American Diabetes Association's 79th Scientific Sessions conference. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.